Psoriasis Drug Development

The involvement of the immune system and the rapid overproduction of skin cells are the primary factors that cause psoriasis symptoms. Therefore, most drugs for psoriasis currently in development are targeted towards these pathways to increase the efficacy of treatments while reducing the adverse effects.


History of psoriasis treatments

Throughout history, the treatments used to manage the symptoms of psoriasis were discovered mainly through experimentation and noting the response of the skin lesions to these treatments. It was in this way that traditional psoriasis treatments, such as coal tar, were initially discovered.

However, advances in our understanding of the pathophysiology of psoriasis have revolutionized how drug discovery studies for the treatment of psoriasis are conducted. For this reason, the drug market for psoriasis treatments is rapidly expanding and is believed to double by 2023.

Medications targeting the action of T cells in the immune system and others that inhibit tumor necrosis factor (TNF) have already entered the market, along with several other similar drugs currently in development.

New drugs in 2015

At the beginning of 2015, both Cosentyx (secukinumab) and Otezla (apremilast) were approved to treat psoriasis.

Cosentyx is manufactured by Novartis and is the first interleukin-17 (IL-17) inhibitor to be approved, indicated for adults with moderate to severe psoriasis. This is a new biologic drug that is a suitable alternative for patients who are unresponsive to other treatments for the condition.

Otezle is manufactured by Celgene and is a selective phosphodiesterase-4 inhibitor, a new drug class that is thought to exist midway between traditional systemic drugs and biologic treatments. Otezle is expected to be helpful in treating severe cases to delay the progression to biological drugs.

Drugs currently in development

The market for pharmaceutical treatments for psoriasis is growing rapidly, with a significant number of new medications that are expected to apply for approval by the United States Food and Drug Administration (FDA) in the next five years.

Medications for administration via injection that are currently in development include:

  • Guselkumab
  • ABP 501
  • GP2017
  • Tregalizumab
  • Cimzia (certolizumab pegol)
  • Cosentyx (secukinumab)
  • Tildrakizumab
  • Namilumab
  • IMO-840
  • BI 655066

Medications for oral administration that are currently in development include:

  • XP23829
  • KD025
  • Alitretinoin
  • ASP015K
  • Apo805K1
  • FP187
  • LEO 22811
  • Baricitinib
  • VB-201
  • CF101

Medications for topical application that are currently in development include:

  • LAS41008
  • Enstilar foam
  • MOL 4239
  • IDP-118
  • AN2728
  • CT 327
  • LAS41004
  • Taclonex
  • LEO 90100
  • PH-10
  • WBI-1001
  • Calcipotriene foam
  • Tofacitinib
  • M518101
  • DFD-01


Further Reading

Last Updated: Jun 10, 2023

Yolanda Smith

Written by

Yolanda Smith

Yolanda graduated with a Bachelor of Pharmacy at the University of South Australia and has experience working in both Australia and Italy. She is passionate about how medicine, diet and lifestyle affect our health and enjoys helping people understand this. In her spare time she loves to explore the world and learn about new cultures and languages.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Smith, Yolanda. (2023, June 10). Psoriasis Drug Development. News-Medical. Retrieved on July 19, 2024 from

  • MLA

    Smith, Yolanda. "Psoriasis Drug Development". News-Medical. 19 July 2024. <>.

  • Chicago

    Smith, Yolanda. "Psoriasis Drug Development". News-Medical. (accessed July 19, 2024).

  • Harvard

    Smith, Yolanda. 2023. Psoriasis Drug Development. News-Medical, viewed 19 July 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Low stress resilience in youth linked to higher psoriasis risk later